Use of recombinant human erythropoietin in a Jehovah's Witness

Koenig, Heidi M.; Levine, Edward A.; Resnick, Daniel J.; Meyer, William J.

doi:10.1016/0952-8180(93)90024-9

Cited by 21 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The same exogenous impetus has been described in autologous blood donation programs, perioperative settings and Jehovah's Witnesses refusing blood transfusion [27][28][29][30][31][32]. The same exogenous impetus has been described in autologous blood donation programs, perioperative settings and Jehovah's Witnesses refusing blood transfusion [27][28][29][30][31][32].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis

Breymann

Richter

Hüttner

et al. 2000

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis

Breymann

Richter

Hüttner

et al. 2000

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…However in both cases, the treatment will be the same and best avoiding blood transfusion. At present, the main treatment options for anemia include oral iron, parenteral iron, the stimulation of hemopoiesis with growth factors (e.g., recombinant human erythropoietin [rhEPO]) and the administration of heterologous blood [33][34][35][36][37][38]. The review will focus on iron therapy only.…”

Section: Treatment Of Iron-deficiency Anemia In Pregnancymentioning

confidence: 99%

Iron deficiency anemia in pregnancy

Breymann

2013

Expert Review of Obstetrics & Gynecology

View full text Add to dashboard Cite

“…A similar effect of exogenous rhEPO has been described in autologous blood donation programmes, in perisurgical settings and for Jehovah's Witnesses refusing blood transfusion. [13,15,17,[18][19][20]. Concerning haemoglobin and haematocrit increase for all treated patients, difference between rhEPO-treated patients and only iron-treated patients was small or even non-existent, if rhEPO was administered subcutaneously.…”

Section: Discussionmentioning

confidence: 99%

“…during autologous blood donations or in perioperative settings [13][14][15][16][17][18][19][20]. rhEPO is also effective if erythropoiesis is blunted, as a result of inadequately low endogenous EPO levels, e.g.…”

Section: Introductionmentioning

confidence: 99%

Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia

Breymann

Zimmermann

Huch

et al. 1996

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. The authors compared the effect of recombinant human erythropoietin (rhEPO) in combination with iron with that of iron therapy only in the treatment of postpartum anaemia. Ninety patients (30 patients/ group) received either rhEPO (300 U kg ÿ 1 , i.v. or s.c., once) and iron (parenteral and oral), or iron therapy only. Erythropoiesis was assessed by haemoglobin and haematocrit increase, absolute reticulocyte counting and reticulocyte flow cytometry. Ferrokinetics was assessed by serum ferritin, transferrin and transferrin saturation measurements. There was no difference before therapy for baseline haematological values or iron status. Patients with endogenous EPO levels below 145 mU mL ÿ 1 had a significant benefit from intravenous rhEPO administration with highest haematocrit and haemoglobin levels 4 and 14 days after therapy. rhEPO-treated groups showed a higher absolute reticulocyte count 1 and 4 days after therapy and an elevated percentage of high fluorescent reticulocytes (HFRs). Parenteral iron therapy caused a significant increase of ferritin and transferrin saturation, while transferrin concentration decreased. Ferritin and transferrin levels were lowest after i.v. administration of rhEPO, 1 and 4 days after therapy. C-reactive protein concentration was highest in patients who underwent caesarean section until the end of the observation period. A single dose of rhEPO in combination with iron was more effective in treating postpartum anaemia than iron therapy only, in patients who had low EPO levels despite peripartal blood loss. Postpartum low endogenous EPO levels might be a consequence of inhibiting inflammatory cytokines that are released after spontaneous or operative deliveries.

show abstract

Use of recombinant human erythropoietin in a Jehovah's Witness

Cited by 21 publications

References 17 publications

Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis

Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis

Iron deficiency anemia in pregnancy

Use of recombinant human erythropoietin in combination with parenteral iron in the treatment of postpartum anaemia

Contact Info

Product

Resources

About